Christopher Jaccoma

Pimavanserin treatment of hallucinations and delusions in patients with Parkinson’s disease dementia: post hoc analysis of the HARMONY trial

Abstract: Introduction: Pimavanserin 34 mg is approved in the US to treat hallucinations and delusions associated with Parkinson’s Disease psychosis (PDP). The efficacy and safety of pima...

Christopher Jaccoma ;

Sanjeev Pathak , MD;

01/19/2023

A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis (PDP)

Abstract: Introduction: Accurate assessment of disability associated with Parkinson’s Disease Psychosis (PDP) is essential and has been poorly studied. Patients often have poor insight on...

Christopher Jaccoma ;

Victor Abler , DO;

01/19/2023